Protein Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Protein Function (Enzymatic & Regulatory, Protein Diagnostics, Vaccines), By Product Type (Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies), By Region & Competition, 2021-2031F
The Global Protein Therapeutics Market is projected to expand from USD 301.19 Billion in 2025 to USD 447.46 Billion by 2031, achieving a CAGR of 6.82%. These therapeutics consist of pharmacologically active substances derived from living organisms, such as monoclonal antibodies and recombinant hormones, which are engineered to replace deficient proteins or target specific disease markers. Market growth is primarily driven by the increasing global prevalence of chronic conditions like oncology and autoimmune disorders that require potent interventions, alongside advancements in bioengineering that enable the synthesis of complex molecules with enhanced efficacy profiles.
Conversely, the sector faces significant challenges due to the high costs associated with development and manufacturing. The complex nature of biologic production demands strict quality control and cold chain logistics, which raises final prices and limits patient access in emerging economies. Reflecting the industry's effort to address these economic barriers, the Pharmaceutical Research and Manufacturers of America reported that there were over 70 approved biosimilars in the United States in 2025, signaling a strong focus on overcoming cost-related impediments to market expansion.
Market Driver
The rising prevalence of chronic diseases and metabolic disorders serves as a major catalyst for the Global Protein Therapeutics Market. As conditions like cancer and diabetes become more widespread, the demand for highly specific interventions provided by protein-based drugs intensifies. This expanding patient pool correlates with a higher utilization of monoclonal antibodies and replacement therapies, particularly in developed regions where diagnosis rates are increasing. Highlighting this urgent need, the American Cancer Society's 'Cancer Facts & Figures 2025' report projected that over 2 million new cancer cases would be diagnosed in the United States in 2025.
Simultaneously, a supportive regulatory environment and accelerated approval pathways are significantly speeding up market entry for new treatments. Regulatory agencies are increasingly adopting streamlined review processes for biologics that address unmet medical needs, reducing development timelines and fostering innovation. This efficiency is evidenced by the Regulatory Affairs Professionals Society's report that the U.S. FDA approved 50 new molecular entities in 2024. Such regulatory support translates into commercial success, as seen in Novo Nordisk's 2025 report, which stated that sales of its GLP-1 based diabetes products reached DKK 149.1 billion in 2024.
Market Challenge
The Global Protein Therapeutics Market confronts a major obstacle regarding the immense capital expenditure needed for product development and manufacturing. Unlike small-molecule drugs, protein therapeutics are large, complex biologics requiring highly specialized production facilities and rigorous quality assurance protocols. This technical complexity demands a massive upfront financial commitment, creating a high barrier to entry for new competitors and straining the resources of existing manufacturers, often forcing companies to set premium prices to recover their investments, which limits the addressable patient population.
This economic strain directly impedes market expansion, especially in cost-sensitive regions with constrained healthcare budgets. The requirement for sophisticated cold chain logistics further increases operational costs, making these life-saving treatments unaffordable for many people globally. The financial intensity of the sector is underscored by the European Federation of Pharmaceutical Industries and Associations, which estimated that the research-based pharmaceutical industry invested ?55 billion in research and development in Europe in 2024, an expenditure level that sustains high unit costs and hinders broader market growth.
Market Trends
The integration of Artificial Intelligence into protein design is fundamentally transforming discovery pipelines by allowing for the de novo generation of therapeutics with optimized properties. Unlike traditional screening methods, generative AI models can predict protein structures and binding affinities with high accuracy, significantly shortening lead optimization timelines. This technological advancement has attracted substantial investment, as evidenced by BioSpace's April 2024 report stating that Xaira Therapeutics launched with over $1 billion in committed capital to advance an AI-driven platform for designing functional molecules.
Furthermore, the acceleration of Antibody-Drug Conjugate (ADC) development marks a critical evolution in oncology, progressing from simple monoclonal antibodies to highly potent armed constructs. Modern ADCs employ sophisticated linker technologies to release cytotoxic payloads exclusively within tumor cells, maximizing efficacy while minimizing systemic toxicity. This potential has driven strategic consolidation, exemplified by Johnson & Johnson's March 2024 announcement that it completed the acquisition of Ambrx Biopharma for approximately $2 billion to integrate its proprietary synthetic biology platform for next-generation ADC design.
Key Market Players
In this report, the Global Protein Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Protein Therapeutics Market.
Available Customizations:
Global Protein Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Conversely, the sector faces significant challenges due to the high costs associated with development and manufacturing. The complex nature of biologic production demands strict quality control and cold chain logistics, which raises final prices and limits patient access in emerging economies. Reflecting the industry's effort to address these economic barriers, the Pharmaceutical Research and Manufacturers of America reported that there were over 70 approved biosimilars in the United States in 2025, signaling a strong focus on overcoming cost-related impediments to market expansion.
Market Driver
The rising prevalence of chronic diseases and metabolic disorders serves as a major catalyst for the Global Protein Therapeutics Market. As conditions like cancer and diabetes become more widespread, the demand for highly specific interventions provided by protein-based drugs intensifies. This expanding patient pool correlates with a higher utilization of monoclonal antibodies and replacement therapies, particularly in developed regions where diagnosis rates are increasing. Highlighting this urgent need, the American Cancer Society's 'Cancer Facts & Figures 2025' report projected that over 2 million new cancer cases would be diagnosed in the United States in 2025.
Simultaneously, a supportive regulatory environment and accelerated approval pathways are significantly speeding up market entry for new treatments. Regulatory agencies are increasingly adopting streamlined review processes for biologics that address unmet medical needs, reducing development timelines and fostering innovation. This efficiency is evidenced by the Regulatory Affairs Professionals Society's report that the U.S. FDA approved 50 new molecular entities in 2024. Such regulatory support translates into commercial success, as seen in Novo Nordisk's 2025 report, which stated that sales of its GLP-1 based diabetes products reached DKK 149.1 billion in 2024.
Market Challenge
The Global Protein Therapeutics Market confronts a major obstacle regarding the immense capital expenditure needed for product development and manufacturing. Unlike small-molecule drugs, protein therapeutics are large, complex biologics requiring highly specialized production facilities and rigorous quality assurance protocols. This technical complexity demands a massive upfront financial commitment, creating a high barrier to entry for new competitors and straining the resources of existing manufacturers, often forcing companies to set premium prices to recover their investments, which limits the addressable patient population.
This economic strain directly impedes market expansion, especially in cost-sensitive regions with constrained healthcare budgets. The requirement for sophisticated cold chain logistics further increases operational costs, making these life-saving treatments unaffordable for many people globally. The financial intensity of the sector is underscored by the European Federation of Pharmaceutical Industries and Associations, which estimated that the research-based pharmaceutical industry invested ?55 billion in research and development in Europe in 2024, an expenditure level that sustains high unit costs and hinders broader market growth.
Market Trends
The integration of Artificial Intelligence into protein design is fundamentally transforming discovery pipelines by allowing for the de novo generation of therapeutics with optimized properties. Unlike traditional screening methods, generative AI models can predict protein structures and binding affinities with high accuracy, significantly shortening lead optimization timelines. This technological advancement has attracted substantial investment, as evidenced by BioSpace's April 2024 report stating that Xaira Therapeutics launched with over $1 billion in committed capital to advance an AI-driven platform for designing functional molecules.
Furthermore, the acceleration of Antibody-Drug Conjugate (ADC) development marks a critical evolution in oncology, progressing from simple monoclonal antibodies to highly potent armed constructs. Modern ADCs employ sophisticated linker technologies to release cytotoxic payloads exclusively within tumor cells, maximizing efficacy while minimizing systemic toxicity. This potential has driven strategic consolidation, exemplified by Johnson & Johnson's March 2024 announcement that it completed the acquisition of Ambrx Biopharma for approximately $2 billion to integrate its proprietary synthetic biology platform for next-generation ADC design.
Key Market Players
- Amgen Inc.
- Eli Lilly and Company.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc
- Merck KGaA
- Pfizer Inc.
- AstraZeneca Plc.
- Teva Pharmaceutical Industries Ltd
- Bristol-Myers Squibb Company
- AbbVie Inc.
In this report, the Global Protein Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Protein Therapeutics Market, By Protein Function
- Enzymatic & Regulatory
- Protein Diagnostics
- Vaccines
- Protein Therapeutics Market, By Product Type
- Blood Clotting Factor
- Erythropoietin
- Follicle Stimulating Hormone
- G-CSF
- Insulin
- Interferons
- Monoclonal Antibodies
- Protein Therapeutics Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Protein Therapeutics Market.
Available Customizations:
Global Protein Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PROTEIN THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Protein Function (Enzymatic & Regulatory, Protein Diagnostics, Vaccines)
5.2.2. By Product Type (Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. NORTH AMERICA PROTEIN THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Protein Function
6.2.2. By Product Type
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Protein Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Protein Function
6.3.1.2.2. By Product Type
6.3.2. Canada Protein Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Protein Function
6.3.2.2.2. By Product Type
6.3.3. Mexico Protein Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Protein Function
6.3.3.2.2. By Product Type
7. EUROPE PROTEIN THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Protein Function
7.2.2. By Product Type
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Protein Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Protein Function
7.3.1.2.2. By Product Type
7.3.2. France Protein Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Protein Function
7.3.2.2.2. By Product Type
7.3.3. United Kingdom Protein Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Protein Function
7.3.3.2.2. By Product Type
7.3.4. Italy Protein Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Protein Function
7.3.4.2.2. By Product Type
7.3.5. Spain Protein Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Protein Function
7.3.5.2.2. By Product Type
8. ASIA PACIFIC PROTEIN THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Protein Function
8.2.2. By Product Type
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Protein Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Protein Function
8.3.1.2.2. By Product Type
8.3.2. India Protein Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Protein Function
8.3.2.2.2. By Product Type
8.3.3. Japan Protein Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Protein Function
8.3.3.2.2. By Product Type
8.3.4. South Korea Protein Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Protein Function
8.3.4.2.2. By Product Type
8.3.5. Australia Protein Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Protein Function
8.3.5.2.2. By Product Type
9. MIDDLE EAST & AFRICA PROTEIN THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Protein Function
9.2.2. By Product Type
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Protein Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Protein Function
9.3.1.2.2. By Product Type
9.3.2. UAE Protein Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Protein Function
9.3.2.2.2. By Product Type
9.3.3. South Africa Protein Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Protein Function
9.3.3.2.2. By Product Type
10. SOUTH AMERICA PROTEIN THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Protein Function
10.2.2. By Product Type
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Protein Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Protein Function
10.3.1.2.2. By Product Type
10.3.2. Colombia Protein Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Protein Function
10.3.2.2.2. By Product Type
10.3.3. Argentina Protein Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Protein Function
10.3.3.2.2. By Product Type
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL PROTEIN THERAPEUTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Amgen Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Eli Lilly and Company.
15.3. F. Hoffmann-La Roche Ltd.
15.4. Johnson & Johnson Services, Inc
15.5. Merck KGaA
15.6. Pfizer Inc.
15.7. AstraZeneca Plc.
15.8. Teva Pharmaceutical Industries Ltd
15.9. Bristol-Myers Squibb Company
15.10. AbbVie Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PROTEIN THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Protein Function (Enzymatic & Regulatory, Protein Diagnostics, Vaccines)
5.2.2. By Product Type (Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. NORTH AMERICA PROTEIN THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Protein Function
6.2.2. By Product Type
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Protein Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Protein Function
6.3.1.2.2. By Product Type
6.3.2. Canada Protein Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Protein Function
6.3.2.2.2. By Product Type
6.3.3. Mexico Protein Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Protein Function
6.3.3.2.2. By Product Type
7. EUROPE PROTEIN THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Protein Function
7.2.2. By Product Type
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Protein Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Protein Function
7.3.1.2.2. By Product Type
7.3.2. France Protein Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Protein Function
7.3.2.2.2. By Product Type
7.3.3. United Kingdom Protein Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Protein Function
7.3.3.2.2. By Product Type
7.3.4. Italy Protein Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Protein Function
7.3.4.2.2. By Product Type
7.3.5. Spain Protein Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Protein Function
7.3.5.2.2. By Product Type
8. ASIA PACIFIC PROTEIN THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Protein Function
8.2.2. By Product Type
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Protein Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Protein Function
8.3.1.2.2. By Product Type
8.3.2. India Protein Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Protein Function
8.3.2.2.2. By Product Type
8.3.3. Japan Protein Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Protein Function
8.3.3.2.2. By Product Type
8.3.4. South Korea Protein Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Protein Function
8.3.4.2.2. By Product Type
8.3.5. Australia Protein Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Protein Function
8.3.5.2.2. By Product Type
9. MIDDLE EAST & AFRICA PROTEIN THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Protein Function
9.2.2. By Product Type
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Protein Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Protein Function
9.3.1.2.2. By Product Type
9.3.2. UAE Protein Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Protein Function
9.3.2.2.2. By Product Type
9.3.3. South Africa Protein Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Protein Function
9.3.3.2.2. By Product Type
10. SOUTH AMERICA PROTEIN THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Protein Function
10.2.2. By Product Type
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Protein Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Protein Function
10.3.1.2.2. By Product Type
10.3.2. Colombia Protein Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Protein Function
10.3.2.2.2. By Product Type
10.3.3. Argentina Protein Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Protein Function
10.3.3.2.2. By Product Type
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL PROTEIN THERAPEUTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Amgen Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Eli Lilly and Company.
15.3. F. Hoffmann-La Roche Ltd.
15.4. Johnson & Johnson Services, Inc
15.5. Merck KGaA
15.6. Pfizer Inc.
15.7. AstraZeneca Plc.
15.8. Teva Pharmaceutical Industries Ltd
15.9. Bristol-Myers Squibb Company
15.10. AbbVie Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
